FDA Launches Global Reliance Disclosure Program for Approval Packages
November 18, 2026


The US Food and Drug Administration has announced the Global Reliance Disclosure Program (GRDP), a program that lets the agency share minimally redacted approval packages, including its detailed scientific and regulatory assessments, directly with companies. Those companies can then give the packages to regulatory authorities outside the United States. The FDA says the program may accelerate patient access to innovative therapies throughout the world.
How the global reliance disclosure program works
The FDA says the program enables it to share approval packages more efficiently. It empowers authorities outside the US to rely on the agency’s science-based review decisions, rather than carry out duplicative and time-consuming product evaluations of their own, while keeping sovereignty over their regulatory decisions.
The program launched with lenacapavir
The GRDP launched on October 30 with a President’s Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. The FDA calls this an especially meaningful starting point given PEPFAR’s life-saving mission to combat HIV/AIDS in some of the world’s most vulnerable populations.
Dr. Reddy’s announced on 2 November 2026 that the FDA had granted tentative approval under PEPFAR for its long-acting lenacapavir injection for PrEP. South Africa’s lenacapavir PrEP rollout had initiated 55,123 people in its first 94 days, the Department of Health said on 8 September 2026, with the count taken as of 7 September. In England, NICE has opened a consultation on draft guidance that does not recommend lenacapavir for HIV PrEP. The evaluation committee found the six-monthly injection is not value for money for the NHS on the evidence it reviewed.
Eligibility, expansion and requests
Applicants must request to participate within 10 calendar days of approval. They must also confirm that the application package is being submitted to a foreign regulatory authority in support of a marketing application. Applicants with eligible applications will receive detailed information in FDA approval letters, and the agency intends to provide the minimally redacted package on an expedited basis.
Requests for approval packages for other purposes will not be processed under the GRDP. They should be submitted as a Freedom of Information Act (FOIA) request.
The GRDP is currently available to PEPFAR tentative approvals and excludes tentatively approved abbreviated new drug application products. The FDA intends to expand it in January 2027 to all novel drugs and biologics, meaning New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The FDA describes the expansion as dramatically broadening the program’s reach and impact.
A pathway for medicines already on the market
The FDA also intends to launch a pathway in early 2027 to expedite an applicant’s ability to request minimally redacted action packages for approved and licensed drugs and biologics. The agency says this is aimed at accelerating global access to medicines already on the US market that it has found to be safe and effective.
Why the FDA frames the program as a global health measure
Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs, said: “The GRDP is a prime example of America First policies improving public health worldwide. The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America’s continued interest in advancing global health under the Trump Administration.”
Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy, said: “In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA’s leadership is most effective when it is collaborative. The GRDP reflects a forward-looking vision of regulatory leadership: one defined not by exclusivity, but by the willingness to share expertise, elevate global standards, and put patients first, wherever they are.”
The release describes the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings as one of the most persistent and consequential challenges in global health. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review, due to limited regulatory capacity and resources.
The release also says harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets. It says this helps ensure the same high-quality therapies reach patients regardless of where they live, including here in the United States.
Source: FDA news release, “FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide”, content current as of 17 November 2026.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.





